Warner Chilcott Plc (WCRX), a drugmaker specializing in women’s health and dermatology, said it has ended efforts to find a buyer for the company. The drugmaker said in April it was weighing options including a possible sale. Bloomberg News reported the company had received interest from strategic and private-equity buyers. Warner Chilcott now will renew a $250 million share buyback program and expects to pay a special cash dividend of $4, the Dublin-based drugmaker said yesterday in a statement.
